Hypera Pharma
 | |
| Company type | Sociedade Anônima |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2001 |
| Headquarters | São Paulo, Brazil |
Key people | Claudio Bergamo,(CEO) |
| Products | Drugs Healthcare Cosmetics |
| Revenue |  US$ 1.8 billion (2013)[1] |
| US$ 108.6 million (2013)[1] | |
Number of employees | 10,252 |
| Subsidiaries | Mantecorp |
| Website | www.hypermarcas.com.br |
Hypermarcas is a Brazilian consumer goods company. The company has a complete portfolio of brands in Brazil, with capital from Brazil, considering jointly market segments in which it operates
Currently, Hypermarcas operates five industrial complexes with 13 different production lines, located in the states of Goias, Santa Catarina, São Paulo and Rio Grande do Sul has a portfolio of brands and products with established demand that the Company has historically provided a solid stream cash. The Company has a directors and shareholders with experience and know-how in the goods of mass consumption. Hypermarcas has extensive experience in identifying, attracting, acquiring and integrating businesses in this sector, the implementation of policies for growth and investment in marketing. These factors make possible the growth of their brands.[citation needed]
Among the products marketed by Hypermarcas, there is a topical solution of chlorhexidine digluconate, used to clean and disinfect small wounds, that is sold under the brand name of "Merthiolate".[2] This is distinguished from thiomersal, which is the traditional organomercury compound sold under the brand name of "Merthiolate".[3]
References
- ^ a b Terra.com (Portuguese language)
- ^ Pharmaceutical company listing.
- ^ Baker, Jeffery P., MD, PhD (2008). "Mercury, Vaccines, and Autism: One Controversy, Three Histories". Am J Public Health. 98 (2): 244–53. doi:10.2105/AJPH.2007.113159. PMC 2376879. PMID 18172138.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
